Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant

Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant

Hepatitis B reactivation can occur with various forms of immunosuppression. Cyclophosphamide, Bortezomib, and Dexamethasone (CYBOR-D) chemotherapy is commonly used for the treatment of multiple myeloma and has not been noted in guidelines to be causative in HBV reactivation. Indeed, current guidelin...

Full description

Bibliographic Details
Main Authors: Majed M. Almaghrabi, Kyle J. Fortinsky, David Wong
Format: Article
Language:English
Published: Hindawi Limited 2017-01-01
Series:Case Reports in Hepatology
Online Access:http://dx.doi.org/10.1155/2017/2463953
id doaj-0be37c31a1104fdf8a55351c29b65a73
record_format Article
spelling doaj-0be37c31a1104fdf8a55351c29b65a732020-11-24T23:55:58ZengHindawi LimitedCase Reports in Hepatology2090-65872090-65952017-01-01201710.1155/2017/24639532463953Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell TransplantMajed M. Almaghrabi0Kyle J. Fortinsky1David Wong2Division of Internal Medicine, University of Toronto, Toronto, ON, CanadaDivision of Hepatology, University of Toronto, Toronto, ON, CanadaDivision of Hepatology, University of Toronto, Toronto, ON, CanadaHepatitis B reactivation can occur with various forms of immunosuppression. Cyclophosphamide, Bortezomib, and Dexamethasone (CYBOR-D) chemotherapy is commonly used for the treatment of multiple myeloma and has not been noted in guidelines to be causative in HBV reactivation. Indeed, current guidelines do not recommend providing antiviral prophylaxis to patients with prior HBV infection. We present a case of HBV reactivation as a result of CYBOR-D and autologous stem cell transplant which is complicated by the patient’s partner who developed acute hepatitis B. Our case highlights the need to review the role of antiviral prophylaxis for patients undergoing treatment of multiple myeloma and also the role of ensuring immunity for close contacts of these patients who may also be at risk.http://dx.doi.org/10.1155/2017/2463953
collection DOAJ
language English
format Article
sources DOAJ
author Majed M. Almaghrabi
Kyle J. Fortinsky
David Wong
spellingShingle Majed M. Almaghrabi
Kyle J. Fortinsky
David Wong
Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant
Case Reports in Hepatology
author_facet Majed M. Almaghrabi
Kyle J. Fortinsky
David Wong
author_sort Majed M. Almaghrabi
title Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant
title_short Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant
title_full Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant
title_fullStr Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant
title_full_unstemmed Severe Acute Hepatitis B in HBV-Vaccinated Partner of a Patient with Multiple Myeloma Treated with Cyclophosphamide, Bortezomib, and Dexamethasone and Autologous Stem Cell Transplant
title_sort severe acute hepatitis b in hbv-vaccinated partner of a patient with multiple myeloma treated with cyclophosphamide, bortezomib, and dexamethasone and autologous stem cell transplant
publisher Hindawi Limited
series Case Reports in Hepatology
issn 2090-6587
2090-6595
publishDate 2017-01-01
description Hepatitis B reactivation can occur with various forms of immunosuppression. Cyclophosphamide, Bortezomib, and Dexamethasone (CYBOR-D) chemotherapy is commonly used for the treatment of multiple myeloma and has not been noted in guidelines to be causative in HBV reactivation. Indeed, current guidelines do not recommend providing antiviral prophylaxis to patients with prior HBV infection. We present a case of HBV reactivation as a result of CYBOR-D and autologous stem cell transplant which is complicated by the patient’s partner who developed acute hepatitis B. Our case highlights the need to review the role of antiviral prophylaxis for patients undergoing treatment of multiple myeloma and also the role of ensuring immunity for close contacts of these patients who may also be at risk.
url http://dx.doi.org/10.1155/2017/2463953
work_keys_str_mv AT majedmalmaghrabi severeacutehepatitisbinhbvvaccinatedpartnerofapatientwithmultiplemyelomatreatedwithcyclophosphamidebortezomibanddexamethasoneandautologousstemcelltransplant
AT kylejfortinsky severeacutehepatitisbinhbvvaccinatedpartnerofapatientwithmultiplemyelomatreatedwithcyclophosphamidebortezomibanddexamethasoneandautologousstemcelltransplant
AT davidwong severeacutehepatitisbinhbvvaccinatedpartnerofapatientwithmultiplemyelomatreatedwithcyclophosphamidebortezomibanddexamethasoneandautologousstemcelltransplant
_version_ 1725460427959173120

Similar Items